• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16732 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Malaysian Health Technology Assessment (MaHTAS) Robotic-assisted surgery for gynaecological disorders
2025     Malaysian Health Technology Assessment (MaHTAS) Apomorphine injection and subcutaneous infusion therapy for advanced Parkinson’s disease
2025     Malaysian Health Technology Assessment (MaHTAS) Microwave ablation for kidney and liver tumours
2025     Malaysian Health Technology Assessment (MaHTAS) 3D-printing for orthosis, prosthesis and exoskeleton
2025     Malaysian Health Technology Assessment (MaHTAS) Laparoscopic indocyanine green sentinel lymph node mapping in endometrial cancer
2025     NIHR Health Services and Delivery Research programme Health visiting in the UK in light of the COVID-19 pandemic experience (RReHOPE): study synopsis
2025     NIHR Health Technology Assessment programme Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviews
2025     NIHR Health Technology Assessment programme Optimal provision of opiate substitution therapy and needle and syringe programmes: a multi-method realist evaluation
2025     NIHR Health Technology Assessment programme Compression Hosiery to Avoid the Post-Thrombotic Syndrome: a synopsis of the CHAPS RCT
2025     NIHR Health Services and Delivery Research programme Proactive integrated consultation-liaison psychiatry for older medical inpatients: The HOME Study RCT of its effectiveness and cost-effectiveness
2025     NIHR Health Technology Assessment programme Accuracy and clinical effectiveness of fetal growth monitoring strategies for the prediction of small for gestational age at birth: a systematic review and meta-analysis
2025     NIHR Health Technology Assessment programme Behavioural weight management interventions for the treatment of obesity: network meta-analysis of trial and real-world individual participant data
2025     NIHR Health Technology Assessment programme Dismantling behavioural weight management interventions: component network meta-analysis of randomised controlled trials and real-world services
2025     NIHR Health Technology Assessment programme Risk assessment tools for predicting transfusion in surgery: a systematic review and meta-analysis
2025     NIHR Health Services and Delivery Research programme Developing palliative and end-of-life care research partnerships in the North East and North Cumbria: a report on the first year of the RIPEN network
2025     The Danish Health Technology Council (DHTC) [Evaluation report concerning supervised walking exercise for patients with intermittent claudication]
2025     National Institute for Health and Care Excellence (NICE) Low-energy contact X-ray brachytherapy for rectal cancer. NICE interventional procedures guidance 809
2025     National Institute for Health and Care Excellence (NICE) Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 1108
2025     National Institute for Health and Care Excellence (NICE) Delgocitinib for treating moderate to severe chronic hand eczema. NICE technology appraisal guidance 1107
2025     National Institute for Health and Care Excellence (NICE) Cabotegravir for preventing HIV-1 in adults and young people. NICE technology appraisal guidance 1106
2025     National Institute for Health and Care Excellence (NICE) Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 1109
2025     National Institute for Health and Care Excellence (NICE) Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal). NICE technology appraisal guidance 1111
2025     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal). NICE technology appraisal guidance 1112
2025     National Institute for Health and Care Excellence (NICE) Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 1110
2025     NIHR Health Technology Assessment programme Brief psychodynamic-interpersonal therapy for adults with a history of self-harm: the SafePIT RCT
2025     Penn Medicine Center for Evidence-based Practice (CEP) Tools for predicting imminent death
2025     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for glycogen storage disease, Type II (GSD II; Pompe disease)
2025     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)
2025     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for mucopolysaccharidosis Type II (MPS II; Hunter syndrome)
2025     NIHR Health Technology Assessment programme Implementation and use of technology-enabled remote monitoring for chronic obstructive pulmonary disease: a rapid qualitative evaluation
2025     NIHR Health Technology Assessment programme An exploration of the factors influencing successful implementation, delivery and outcomes in an intensive care sedation study: process evaluation of the A2B RCT
2025     NIHR Health Technology Assessment programme High or low dose oxytocin for nulliparous women delayed in the first stage of labour: the HOLDS RCT
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of a standardised diagnostic assessment for children and adolescents with emotional difficulties: the STADIA multi-centre RCT
2025     NIHR Health Technology Assessment programme The Knee Arthroplasty versus Joint Distraction Study for Osteoarthritis (KARDS): lessons learnt from an internal pilot trial
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
2025     NIHR Health Services and Delivery Research programme Evidence of the impact on and views of NHS staff following a colleague’s suicide to inform postvention guidance: a multi-methods study
2025     NIHR Health Technology Assessment programme Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson’s disease: the ADepT-PD RCT pilot
2025     NIHR Health Technology Assessment programme Swabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT
2025     NIHR Health Technology Assessment programme RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study
2025     NIHR Health Technology Assessment programme Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: the UK Mini Mitral multicentre RCT
2025     NIHR Health Technology Assessment programme Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension: CONFORM-OH pilot RCT and economic evaluation
2025     NIHR Health Technology Assessment programme Treatment effect modifiers of cognitive behaviour therapy in people with psychosis: an individual participant data meta-analysis of RCTs
2025     NIHR Health Technology Assessment programme Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients: The PEACH mixed methods study
2025     NIHR Health Services and Delivery Research programme Development and implementation of a digital health intervention in routine care for long COVID patients: a comprehensive synopsis
2025     National Institute for Health and Care Excellence (NICE) VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. NICE interventional procedures guidance 808
2025     National Institute for Health and Care Excellence (NICE) VA ECMO for severe acute heart failure in adults. NICE interventional procedures guidance 807
2025     National Institute for Health and Care Excellence (NICE) Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal). NICE technology appraisal guidance 1100
2025     National Institute for Health and Care Excellence (NICE) Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy. NICE technology appraisal guidance 1099
2025     National Institute for Health and Care Excellence (NICE) Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over. NICE technology appraisal guidance 1101
2025     National Institute for Health and Care Excellence (NICE) Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor. NICE technology appraisal guidance 1103
2025     National Institute for Health and Care Excellence (NICE) Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 1105
2025     National Institute for Health and Care Excellence (NICE) Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal). NICE technology appraisal guidance 1104
2025     National Institute for Health and Care Excellence (NICE) Iptacopan for treating complement 3 glomerulopathy (terminated appraisal). NICE technology appraisal guidance 1102
2025     NIHR Health Technology Assessment programme Microfracture with or without collagen scaffold insertion for adults with chondral or osteochondral defects of the knee: the SISMIC RCT and its challenges during and after the COVID-19 pandemic
2025     NIHR Health Technology Assessment programme Acceptance and commitment therapy for people living with motor neuron disease: the COMMEND feasibility study and randomised controlled trial
2025     Norwegian Medical Products Agency (NOMA) Ketamine for acute suicidal ideation. Protocol for a health technology assessment
2025     NIHR Health Services and Delivery Research programme Design and deployment of digital health interventions to reduce the risk of the digital divide and to inform development of the living with COVID recovery: a systematic scoping review
2025     Austrian Institute for Health Technology Assessment (AIHTA) Further development of the program on preventive health check-ups: screening for chronic kidney disease – a rapid review of benefits, harms and target populations
2025     NIHR Health Services and Delivery Research programme Effectiveness and cost-effectiveness of community perinatal mental health services on access, experience, recovery/relapse and obstetric and neonate outcomes: the ESMI-II mixed-methods study
2025     NIHR Health Technology Assessment programme Algorithm-based remote monitoring of heart failure risk data in people with cardiac implantable electronic devices: a systematic review and cost-effectiveness analysis
2025     Scottish Health Technologies Group (SHTG) Optune Gio® tumour-treating field therapy
2025     NIHR Health Technology Assessment programme Rapid diagnostic tests to inform clinical decision-making for antifungal stewardship in the ICU: a qualitative study with NHS staff, patients, and their legal representatives
2025     NIHR Health Technology Assessment programme Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation
2025     NIHR Health Services and Delivery Research programme Strategies to manage emergency ambulance telephone callers with sustained high needs: the STRETCHED mixed-methods evaluation with linked data
2025     NIHR Health Services and Delivery Research programme Accessibility and acceptability of perinatal mental health services for women from ethnic minority groups: a synopsis of the PAAM study
2025     Austrian Institute for Health Technology Assessment (AIHTA) Digital health technologies for self-identification of the risk of perinatal mental illness
2025     Austrian Institute for Health Technology Assessment (AIHTA) Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma
2025     National Institute for Health and Care Excellence (NICE) Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis. NICE technology appraisal guidance 1096
2025     National Institute for Health and Care Excellence (NICE) Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable. NICE technology appraisal guidance 1097
2025     National Institute for Health and Care Excellence (NICE) Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 1098
2025     Health Information and Quality Authority (HIQA) Advice to the Minister for Health to inform decision-making around the design and delivery of urgent and emergency healthcare services in the HSE Mid West region of Ireland
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Scopia application for colonoscopy quality control
2025     NIHR Health Technology Assessment programme Effectiveness of surgical interventions in patients with severe pressure ulcers: the SIPS mixed-methods exploratory study
2025     NIHR Health Technology Assessment programme A group intervention for parents and carers to recognise and understand restricted and repetitive behaviour in autistic children: a multisite RCT
2025     NIHR Health Technology Assessment programme Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral in primary care. A systematic review, meta-analysis and cost-effectiveness analysis
2025     NIHR Health Services and Delivery Research programme Identifying acceptable and effective methods of assessing perinatal anxiety: the MAP study
2025     NIHR Health Technology Assessment programme Perioperative oxygen therapy in patients undergoing surgical procedures: an overview of systematic reviews and meta-analyses
2025     NIHR Health Services and Delivery Research programme ‘Come and work here!’ Qualitative research exploring community-led initiatives to improve healthcare recruitment and retention in remote and rural areas
2025     Health Technology Wales (HTW) Digital rehabilitation and self-management interventions for chronic kidney disease
2025     NIHR Health Services and Delivery Research programme Team-based motivational engagement intervention in young people with first-episode psychosis: the EYE-2 cluster RCT with economic and process evaluation
2025     NIHR Health Services and Delivery Research programme Post-pandemic planning for maternity care for local, regional, and national maternity systems across the four nations: a mixed-methods study
2025     NIHR Health Technology Assessment programme Diagnostic strategies for suspected acute aortic syndrome: systematic review, meta-analysis, decision-analytic modelling and value of information analysis
2025     Health Technology Wales (HTW) Long length peripheral intravenous catheters for patients with difficult intravenous access
2025     NIHR Health and Social Care Delivery Program After the disruptive innovation: how remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025     NIHR Health and Social Care Delivery Program Remote and digital services in UK general practice 2021–2023: the Remote by Default 2 longitudinal qualitative study synopsis
2025     National Institute for Health and Care Excellence (NICE) Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen. NICE technology appraisal guidance 1087
2025     National Institute for Health and Care Excellence (NICE) Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence. NICE technology appraisal guidance 1086
2025     National Institute for Health and Care Excellence (NICE) Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over. NICE technology appraisal guidance 1088
2025     National Institute for Health and Care Excellence (NICE) Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 1089
2025     National Institute for Health and Care Excellence (NICE) Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma. NICE technology appraisal guidance 1090
2025     National Institute for Health and Care Excellence (NICE) Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments. NICE technology appraisal guidance 1091
2025     National Institute for Health and Care Excellence (NICE) Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer. NICE technology appraisal guidance 1092
2025     National Institute for Health and Care Excellence (NICE) Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over. NICE technology appraisal guidance 1093
2025     National Institute for Health and Care Excellence (NICE) Guselkumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 1095
2025     National Institute for Health and Care Excellence (NICE) Guselkumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 1094
2025     NIHR Health and Social Care Delivery Program Optimising the delivery and impacts of interventions to improve hospital doctors’ workplace wellbeing in the NHS: The Care Under Pressure 3 realist evaluation study
2025     NIHR Health Technology Assessment programme Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs)
2025     NIHR Health and Social Care Delivery Program Meeting the needs of women in the perinatal period, who use or are in treatment for using drugs: a mixed-methods systematic review
2025     NIHR Health Technology Assessment programme Eradication of Helicobacter pylori for prevention of aspirin-associated peptic ulcer bleeding in adults over 65 years: the HEAT RCT
2025     Austrian Institute for Health Technology Assessment (AIHTA) Temporary nitinol implantation for the treatment of benign prostatic hyperplasia